Yangshan Medical completes Pre-A funding round to support commercialization of China's first unobstructed surgical robot

Yangshan Medical, a developer of robotic systems for oral surgery, recently completed a Pre-A funding round raising tens of millions. The round was jointly led by the specialized healthcare investment firm Sunland Fund and Marathon Venture Partners, with existing shareholder BlueRun Ventures, a well-known early-stage technology investor, continuing its support and participating in this follow-on investment.

Yangshan Medical utilizes robotics, artificial intelligence, and passive innovative medical devices to deliver end-to-end solutions for oral and maxillofacial surgery. Its independently developed surgical robot—China's first to adopt a novel navigation technology that eliminates line-of-sight obstruction—is poised for application in dental implant surgery. Distinguished by core advantages including true registration-free operation, unobstructed workflow, interference resistance, rapid procedure times, a short learning curve, and a compact footprint, the system is further enhanced by Yangshan Medical's proprietary AI technology platform to assist surgeons in performing oral surgeries with greater efficiency and precision.

Another of Yangshan Medical's products, the Dental Implant Distractor (DID), represents a world-first innovation that revolutionizes the traditional vascularized fibula graft procedure used in mandibular defect reconstruction. This achievement received the Second Prize of the National Science and Technology Progress Award in 2019 and entered the National Medical Products Administration's (NMPA) special review channel for innovative medical devices in 2025.